BWH Faculty Shine at AHA Sessions
BWH’s Elliott Antman and Scientific Sessions vice-chair Robert Harrington, MD |
BWH was represented in full force at this year's American Heart Association (AHA) Scientific Sessions Nov. 12-16 in Orlando, Fla. The event drew 20,000 attendees from more than 100 countries. BWH faculty was on hand to receive awards, deliver named lectures and present late-breaking research. Many of the research findings presented by BWH faculty made national news in major publications such as The Wall Street Journal and USA Today.
"These presentations and lectures were very well-received," said Elliott Antman, MD, BWH Cardiovascular Division, senior investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, and AHA Scientific Sessions chairman. "It is wonderful to see one's colleagues have the opportunity to present their work and have it discussed by their peers in the best forum in the world for that kind of activity."
AHA Accolades
Five BWH faculty members took to the stage to receive awards and deliver lectures.
Late-Breaking Snapshots
BWH representation was notably larger than usual in the Late-Breaking Clinical Trial sessions, where researchers presented work that touched on the implications of personalized medicine and the effect of co-payments on medication adherence, among other research. BWH faculty captured the attention of colleagues and media around the country with their intriguing findings.
Rivaroxaban in Patients After an Acute Coronary Syndrome
Jessica L. Mega, MD, MPH, and Eugene Braunwald, MD, Cardiovascular Division
Full Coverage for Preventive Medications After Myocardial Infarction
Niteesh K. Choudhry, MD, PhD, Division of Pharmacoepidemiology and Pharmacoeconomics
Apixaban Versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
Samuel Z. Goldhaber, MD, director, BWH Venous Thromboembolism Research Group
Increasing the Dose of Clopidogrel Based on CYP2C19 Genotype in Patients With Cardiovascular Disease
Jessica L. Mega MD, MPH, Cardiovascular Division
Cardiac Stem cells in Patients With Ischaemic Cardiomyopathy (SCIPIO): Initial Result of a Randomised Phase 1 Trial
Piero Anversa, MD, departments of Anesthesiology and Medicine, Division of Cardiovascular Medicine
Recap, Looking Ahead
Scientific Sessions is the AHA's largest meeting of researchers and health care professionals focused on combating cardiovascular disease and stroke. This year's event saw over 9,000 submitted original research abstracts, with 4,238 accepted and presented across 447 sessions. Attendees had the option to select from 742 individual sessions, which included invited, late-breaking clinical trial, plenary and special sessions among others.
Next year's Scientific Sessions will be held in Los Angeles, Nov. 3-7, which Antman will also chair. Those interested can submit abstracts beginning April 17, 2012. Learn more about next year's event.